Preload Image
Preload Image
Report Store mobile icon
Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Outlook, 2030

Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Outlook, 2030

2025

Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Outlook, 2030

Global amyotrophic lateral sclerosis treatment(Medication, Stem Cell Therapy, Others)market will reach $762.3 million by 2027, growing by 5.8% annually over 2020-2027.

Buy Now Get Free sample

New Report Guarantee

If you purchase this report now and we update it in next 100 days, get it free!

The global Amyotrophic Lateral Sclerosis (ALS) treatment market is experiencing significant growth due to heightened awareness, progress in medical research, and the increasing prevalence of the disease. ALS, commonly referred to as Lou Gehrig’s disease, is a degenerative neurological condition that impacts nerve cells in the brain and spinal cord, resulting in the loss of muscle control. This devastating illness currently lacks a known cure, yet ongoing efforts in medical research and drug development are providing new hope for those affected. The increasing emphasis on neurodegenerative disease research, financial support from governments, and innovations in pharmaceuticals are propelling the growth of the ALS treatment market. The market is primarily fueled by the rising incidence of ALS globally. While the disease is categorized as rare, its effects are significant, impacting thousands of people each year. The precise cause of ALS remains unidentified, though it is thought to be associated with genetic mutations, environmental influences, and autoimmune issues. The condition leads to escalating muscle weakness, challenges in speech, difficulties in swallowing, and respiratory failure, ultimately culminating in death. Given the aggressive nature of ALS, there is a strong demand for effective treatment options that can decelerate disease progression and enhance patients' quality of life.

Global amyotrophic lateral sclerosis treatment market will reach $762.3 million by 2027, growing by 5.8% annually over 20202027. At present, the treatment landscape for ALS features a mix of medications, physical therapy, speech therapy, and assistive devices to alleviate symptoms and extend survival. The two FDAapproved medications, Riluzole and Edaravone, have demonstrated potential in slowing down the disease's progression, although their effectiveness can differ from one patient to another. Riluzole operates by diminishing the release of glutamate, a neurotransmitter that may lead to nerve cell injury, while Edaravone functions as an antioxidant to mitigate oxidative stress in motor neurons. Nevertheless, these treatments provide only limited benefits, motivating researchers to investigate novel therapies, genebased interventions, and stem cell treatments. Biotechnology and pharmaceutical firms are investing significantly in the creation of new ALS treatments, which encompass gene therapy, stem cell transplantations, and neuroprotective medications. Companies are concentrating on targeting genetic mutations like SOD1 and C9orf72, which are associated with familial ALS occurrences. Furthermore, precision medicine and customized treatment strategies are gaining popularity, offering tailored therapies according to a patient’s genetic makeup. Clinical trials for new drug candidates, including antisense oligonucleotides (ASOs), monoclonal antibodies, and smallmolecule drugs, are on the rise globally, further enhancing market expansion.

What's Inside a Bonafide Research`s industry report?

A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.

Download Sample


The worldwide ALS (Amyotrophic Lateral Sclerosis) market is shaped by significant countries and regions, each making considerable contributions to the market's growth and progress. North America, especially the United States, occupies a leading share in the ALS treatment sector. This is attributable to the high incidence of the disease, a wellestablished healthcare system, and substantial funding in ALS research and clinical trials. The U. S. hosts major pharmaceutical firms engaged in the development and distribution of ALS treatments, including drugs such as Riluzole, Radicava, and other therapies. Moreover, the American healthcare system fosters advanced treatment alternatives and clinical trials, resulting in the swift adoption of new therapies. Europe represents another key area in the ALS market, with nations like Germany, France, and the United Kingdom taking on essential roles. Europe is witnessing a growing ALS patient demographic and possesses a solid network of medical institutions dedicated to research. European nations also benefit from favorable reimbursement policies that enhance the availability of ALS treatments. The European Medicines Agency (EMA) has actively participated in the authorization of ALS drugs, further propelling market growth within the region. AsiaPacific, encompassing nations such as Japan, China, and India, is experiencing a rising demand for ALS treatments. Japan has one of the highest occurrences of ALS globally, contributing to the growth of the market in this area. China and India are seeing advancements in healthcare systems and awareness, which is anticipated to boost the uptake of ALS therapies. Latin America and the Middle East are also emerging markets, characterized by increasing healthcare access and an enhanced focus on neurodegenerative diseases.

The worldwide market for ALS (Amyotrophic Lateral Sclerosis) treatments is divided by treatment type into various submarkets, each contributing uniquely to the total revenue. The medication segment represents a substantial portion, encompassing drugs like Riluzole (Rilutek), which is utilized to slow the progression of the disease, and Radicava (Edaravone), recognized for its neuroprotective properties. Tiglutik (Thickened Riluzole), a formulation created for patients who have difficulty swallowing, is another important component. Nuedexta, an FDAapproved medication for addressing pseudobulbar affect in ALS patients, also plays a significant role. The stem cell therapy market is gaining traction as a potential revolutionary treatment intended to regenerate damaged nerve cells. Furthermore, there are other treatments on the market, which encompass supportive therapies and interventions that alleviate symptoms or enhance quality of life. Collectively, these segments propel the global ALS treatment market, with an expected annual revenue rise from 2017 to 2027. The global ALS (Amyotrophic Lateral Sclerosis) market is classified based on ALS types into Sporadic ALS and Familial ALS. Sporadic ALS is the most prevalent variant, constituting around 9095% of ALS instances. It arises randomly, without any discernible hereditary association, and its incidence is on the rise due to aging demographics. The treatment market aimed at sporadic ALS is anticipated to yield substantial revenue growth from 2017 to 2027 as the demand for effective therapies increases globally. Familial ALS, although less common, accounts for approximately 510% of instances and is inherited genetically. The market for familial ALS treatments remains smaller yet still vital, with therapies targeting particular genetic mutations. Both segments are advancing research and development in the ALS market, with endeavors focused on deciphering disease mechanisms and formulating more personalized therapies. The growth in the markets for both types is driven by progress in medication, stem cell therapies, and genetic research.

The ALS treatment market is further categorized based on distribution channels, which consist of Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Other Distribution Channels. Hospital Pharmacies represent a significant portion, as they serve as a vital source for prescriptionbased ALS treatments, particularly for patients in advanced stages. These pharmacies provide specialized services, and medications such as Riluzole and Edaravone are frequently dispensed here. Retail Pharmacies also have an important role in the distribution of ALS treatments, offering access to a wide array of medications for patients. These establishments are essential for patients who need medications for managing symptoms and ongoing care. Online Pharmacies are quickly increasing in popularity due to the convenience they provide, enabling patients and caregivers to order prescriptions directly from their homes. Online platforms also possess the ability to lower costs and offer a greater variety of products, especially in areas where physical pharmacies are scarce. Moreover, Other Distribution Channels, such as direct sales from manufacturers, research institutions, and patient assistance programs, aid in market expansion. These distribution channels have gained momentum due to the rising digitalization of healthcare and the growth of telemedicine. As patient access to treatment options improves, the demand for ALS therapies through numerous distribution channels is anticipated to increase steadily, contributing to overall market growth. From 2017 to 2027, these channels will continue to evolve as key players aimed at enhancing the availability and accessibility of ALS treatments globally.

Make this report your own

Have queries/questions regarding a report

Take advantage of intelligence tailored to your business objective

Sikandar Kesari

Sikandar Kesari

Research Analyst



Considered in this report
• Historic Year: 2019
• Base year: 2024
• Estimated year: 2025
• Forecast year: 2030

Aspects covered in this report
• Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market with its value and forecast along with its segments
• Various drivers and challenges
• On-going trends and developments
• Top profiled companies
• Strategic recommendation
Based on Treatment Type, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
• Medication
• Riluzole (Rilutek)
• Radicava (Edaravone)
• Tiglutik (Thickened Riluzole)
• Nuedexta
• Stem Cell Therapy
• Other Treatments

Based on ALS Type, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
• Sporadic ALS
• Familial ALS

Don’t pay for what you don’t need. Save 30%

Customise your report by selecting specific countries or regions

Specify Scope Now
Sikandar Kesari


Based on Distribution Channel, the global market is segmented into the following sub-markets with annual revenue ($ mn) for 2017-2027 included in each section.
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• Other Distribution Channels
The approach of the report:
This report consists of a combined approach of primary as well as secondary research. Initially, secondary research was used to get an understanding of the market and listing out the companies that are present in the market. The secondary research consists of third-party sources such as press releases, annual report of companies, analyzing the government generated reports and databases. After gathering the data from secondary sources primary research was conducted by making telephonic interviews with the leading players about how the market is functioning and then conducted trade calls with dealers and distributors of the market. Post this we have started doing primary calls to consumers by equally segmenting consumers in regional aspects, tier aspects, age group, and gender. Once we have primary data with us we have started verifying the details obtained from secondary sources.

Intended audience
This report can be useful to industry consultants, manufacturers, suppliers, associations & organizations related to agriculture industry, government bodies and other stakeholders to align their market-centric strategies. In addition to marketing & presentations, it will also increase competitive knowledge about the industry.

Table of Contents

  • 1 Introduction 9
  • 1.1 Industry Definition and Research Scope 9
  • 1.1.1 Industry Definition 9
  • 1.1.2 Research Scope 10
  • 1.2 Research Methodology 13
  • 1.2.1 Overview of Market Research Methodology 13
  • 1.2.2 Market Assumption 14
  • 1.2.3 Secondary Data 14
  • 1.2.4 Primary Data 14
  • 1.2.5 Data Filtration and Model Design 15
  • 1.2.6 Market Size/Share Estimation 16
  • 1.2.7 Research Limitations 17
  • 1.3 Executive Summary 18
  • 2 Market Overview and Dynamics 20
  • 2.1 Market Size and Forecast 20
  • 2.1.1 Impact of COVID-19 on World Economy 21
  • 2.1.2 Impact of COVID-19 on the Market 23
  • 2.2 Major Growth Drivers 25
  • 2.3 Market Restraints and Challenges 29
  • 2.4 Emerging Opportunities and Market Trends 32
  • 2.5 Porter’s Fiver Forces Analysis 36
  • 3 Segmentation of Global Market by Treatment Type 40
  • 3.1 Market Overview by Treatment Type 40
  • 3.2 Medication 42
  • 3.3 Stem Cell Therapy 44
  • 3.4 Other Treatments 45
  • 4 Segmentation of Global Market by ALS Type 46
  • 4.1 Market Overview by ALS Type 46
  • 4.2 Sporadic ALS 48
  • 4.3 Familial ALS 49
  • 5 Segmentation of Global Market by Distribution Channel 50
  • 5.1 Market Overview by Distribution Channel 50
  • 5.2 Hospital Pharmacies 52
  • 5.3 Retail Pharmacies 53
  • 5.4 Online Pharmacies 54
  • 5.5 Other Distribution Channels 55
  • 6 Segmentation of Global Market by Region 56
  • 6.1 Geographic Market Overview 2020-2027 56
  • 6.2 North America Market 2020-2027 by Country 60
  • 6.2.1 Overview of North America Market 60
  • 6.2.2 U.S. 63
  • 6.2.3 Canada 66
  • 6.2.4 Mexico 68
  • 6.3 European Market 2020-2027 by Country 70
  • 6.3.1 Overview of European Market 70
  • 6.3.2 UK 73
  • 6.3.3 France 75
  • 6.3.4 Germany 77
  • 6.3.5 Spain 79
  • 6.3.6 Italy 81
  • 6.3.7 Russia 83
  • 6.3.8 Rest of European Market 85
  • 6.4 Asia-Pacific Market 2020-2027 by Country 87
  • 6.4.1 Overview of Asia-Pacific Market 87
  • 6.4.2 China 90
  • 6.4.3 Japan 92
  • 6.4.4 India 95
  • 6.4.5 Australia 97
  • 6.4.6 South Korea 99
  • 6.4.7 Rest of APAC Region 101
  • 6.5 South America Market 2020-2027 by Country 103
  • 6.5.1 Argentina 106
  • 6.5.2 Brazil 108
  • 6.5.3 Chile 110
  • 6.5.4 Rest of South America Market 112
  • 6.6 MEA Market 2020-2027 by Country 113
  • 6.6.1 UAE 116
  • 6.6.2 Saudi Arabia 118
  • 6.6.3 South Africa 120
  • 6.6.4 Other National Markets 122
  • 7 Competitive Landscape 123
  • 7.1 Overview of Key Vendors 123
  • 7.2 New Product Launch, Partnership, Investment, and M&A 126
  • 7.3 Company Profiles 127
  • AB Science SA 127
  • Amylyx Pharmaceuticals Inc. 129
  • Biogen Inc. 130
  • Biohaven Pharmaceutical Holding Co., Ltd. 131
  • BrainStorm Cell Limited 132
  • Corestem, Inc. 133
  • F.Hoffmann-La Roche AG 134
  • Ionis Pharmaceuticals, Inc. 135
  • Mitsubishi Tanabe Pharma Corporation 136
  • Otsuka Pharmaceutical Co., Ltd. 137
  • Sun Pharmaceutical Industries Ltd. 138
  • RELATED REPORTS 139

Table 1. Snapshot of Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Balanced Perspective, 2020-2027 19
Table 2. Growth Rate of World GDP, 2020-2022 22
Table 3. Main Product Trends and Market Opportunities in Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market 32
Table 4. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn 40
Table 5. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Medication by Type, 2017-2027, $ mn 43
Table 6. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn 46
Table 7. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn 50
Table 8. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Region, 2017-2027, $ mn 57
Table 9. Leading National Amyotrophic Lateral Sclerosis (ALS) Treatment Market, 2020 and 2027, $ mn 59
Table 10. North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Country, 2017-2027, $ mn 62
Table 11. U.S. Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn 65
Table 12. U.S. Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn 65
Table 13. U.S. Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn 65
Table 14. Canada Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn 67
Table 15. Canada Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn 67
Table 16. Canada Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn 67
Table 17. Mexico Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn 69
Table 18. Mexico Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn 69
Table 19. Mexico Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn 69
Table 20. Europe Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Country, 2017-2027, $ mn 72
Table 21. UK Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn 74
Table 22. UK Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn 74
Table 23. UK Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn 74
Table 24. France Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn 76
Table 25. France Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn 76
Table 26. France Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn 76
Table 27. Germany Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn 78
Table 28. Germany Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn 78
Table 29. Germany Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn 78
Table 30. Spain Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn 80
Table 31. Spain Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn 80
Table 32. Spain Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn 80
Table 33. Italy Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn 82
Table 34. Italy Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn 82
Table 35. Italy Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn 82
Table 36. Russia Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn 84
Table 37. Russia Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn 84
Table 38. Russia Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn 84
Table 39. Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Rest of Europe by Country, 2017-2027, $ mn 86
Table 40. APAC Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Country, 2017-2027, $ mn 89
Table 41. China Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn 91
Table 42. China Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn 91
Table 43. China Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn 91
Table 44. Japan Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn 94
Table 45. Japan Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn 94
Table 46. Japan Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn 94
Table 47. India Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn 96
Table 48. India Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn 96
Table 49. India Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn 96
Table 50. Australia Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn 98
Table 51. Australia Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn 98
Table 52. Australia Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn 98
Table 53. South Korea Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn 100
Table 54. South Korea Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn 100
Table 55. South Korea Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn 100
Table 56. Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Rest of APAC by Country/Region, 2017-2027, $ mn 102
Table 57. South America Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Country, 2017-2027, $ mn 105
Table 58. Argentina Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn 107
Table 59. Argentina Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn 107
Table 60. Argentina Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn 107
Table 61. Brazil Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn 109
Table 62. Brazil Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn 109
Table 63. Brazil Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn 109
Table 64. Chile Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn 111
Table 65. Chile Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn 111
Table 66. Chile Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn 111
Table 67. MEA Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Country, 2017-2027, $ mn 115
Table 68. UAE Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn 117
Table 69. UAE Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn 117
Table 70. UAE Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn 117
Table 71. Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn 119
Table 72. Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn 119
Table 73. Saudi Arabia Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn 119
Table 74. South Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2017-2027, $ mn 121
Table 75. South Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2017-2027, $ mn 121
Table 76. South Africa Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2017-2027, $ mn 121
Table 77. AB Science SA: Company Snapshot 127
Table 78. AB Science SA: Business Segmentation 127
Table 79. AB Science SA: Product Portfolio 128
Table 80. AB Science SA: Revenue, 2017-2019, $ mn 128

Figure 1. Research Method Flow Chart 13
Figure 2. Bottom-up Approach and Top-down Approach for Market Estimation 16
Figure 3. Global Market Forecast in Optimistic, Conservative and Balanced Perspectives, 2020-2027 18
Figure 4. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market, 2017-2027, $ mn 20
Figure 5. Impact of COVID-19 on Business 23
Figure 6. Primary Drivers and Impact Factors of Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market 25
Figure 7. Worldwide Geriatric Population (60 years and above) by Regions, 2015 & 2030, million 28
Figure 8. Primary Restraints and Impact Factors of Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market 29
Figure 9. Investment Opportunity Analysis 33
Figure 10. Porter’s Fiver Forces Analysis of Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market 36
Figure 11. Breakdown of Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Treatment Type, 2020-2027, % of Revenue 40
Figure 12. Contribution to Global 2021-2027 Cumulative Revenue by Treatment Type, Value ($ mn) and Share (%) 41
Figure 13. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Medication, 2017-2027, $ mn 42
Figure 14. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Stem Cell Therapy, 2017-2027, $ mn 44
Figure 15. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Other Treatments, 2017-2027, $ mn 45
Figure 16. Breakdown of Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market by ALS Type, 2020-2027, % of Revenue 46
Figure 17. Contribution to Global 2021-2027 Cumulative Revenue by ALS Type, Value ($ mn) and Share (%) 47
Figure 18. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Sporadic ALS, 2017-2027, $ mn 48
Figure 19. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Familial ALS, 2017-2027, $ mn 49
Figure 20. Breakdown of Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Distribution Channel, 2020-2027, % of Revenue 51
Figure 21. Contribution to Global 2021-2027 Cumulative Revenue by Distribution Channel, Value ($ mn) and Share (%) 51
Figure 22. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Hospital Pharmacies, 2017-2027, $ mn 52
Figure 23. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Retail Pharmacies, 2017-2027, $ mn 53
Figure 24. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Online Pharmacies, 2017-2027, $ mn 54
Figure 25. Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market: Other Distribution Channels, 2017-2027, $ mn 55
Figure 26. Global Market Snapshot by Region 56
Figure 27. Geographic Spread of Worldwide Amyotrophic Lateral Sclerosis (ALS) Treatment Market, 2020-2027, % of Revenue 57
Figure 28. Contribution to Global 2021-2027 Cumulative Revenue by Region, Value ($ mn) and Share (%) 58
Figure 29. North American Amyotrophic Lateral Sclerosis (ALS) Treatment Market, 2017-2027, $ mn 61
Figure 30. Breakdown of North America Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Country, 2020 and 2027, % of Revenue 61
Figure 31. Contribution to North America 2021-2027 Cumulative Revenue by Country, Value ($ mn) and Share (%) 62
Figure 32. U.S. Amyotrophic Lateral Sclerosis (ALS) Treatment Market, 2017-2027, $ mn 64
Figure 33. Canada Amyotrophic Lateral Sclerosis (ALS) Treatment Market, 2017-2027, $ mn 66
Figure 34. Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Mexico, 2017-2027, $ mn 68
Figure 35. European Amyotrophic Lateral Sclerosis (ALS) Treatment Market, 2017-2027, $ mn 71
Figure 36. Breakdown of European Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Country, 2020 and 2027, % of Revenue 71
Figure 37. Contribution to Europe 2021-2027 Cumulative Revenue by Country, Value ($ mn) and Share (%) 72
Figure 38. Amyotrophic Lateral Sclerosis (ALS) Treatment Market in UK, 2017-2027, $ mn 73
Figure 39. Amyotrophic Lateral Sclerosis (ALS) Treatment Market in France, 2017-2027, $ mn 75
Figure 40. Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Germany, 2017-2027, $ mn 77
Figure 41. Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Spain, 2017-2027, $ mn 79
Figure 42. Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Italy, 2017-2027, $ mn 81
Figure 43. Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Russia, 2017-2027, $ mn 83
Figure 44. Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Rest of Europe, 2017-2027, $ mn 85
Figure 45. Asia-Pacific Amyotrophic Lateral Sclerosis (ALS) Treatment Market, 2017-2027, $ mn 88
Figure 46. Breakdown of APAC Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Country, 2020 and 2027, % of Revenue 88
Figure 47. Contribution to APAC 2021-2027 Cumulative Revenue by Country, Value ($ mn) and Share (%) 89
Figure 48. Amyotrophic Lateral Sclerosis (ALS) Treatment Market in China, 2017-2027, $ mn 90
Figure 49. Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Japan, 2017-2027, $ mn 93
Figure 50. Amyotrophic Lateral Sclerosis (ALS) Treatment Market in India, 2017-2027, $ mn 95
Figure 51. Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Australia, 2017-2027, $ mn 97
Figure 52. Amyotrophic Lateral Sclerosis (ALS) Treatment Market in South Korea, 2017-2027, $ mn 99
Figure 53. Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Rest of APAC, 2017-2027, $ mn 101
Figure 54. South America Amyotrophic Lateral Sclerosis (ALS) Treatment Market, 2017-2027, $ mn 104
Figure 55. Breakdown of South America Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Country, 2020 and 2027, % of Revenue 104
Figure 56. Contribution to South America 2021-2027 Cumulative Revenue by Country, Value ($ mn) and Share (%) 105
Figure 57. Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Argentina, 2017-2027, $ mn 106
Figure 58. Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Brazil, 2017-2027, $ mn 108
Figure 59. Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Chile, 2017-2027, $ mn 110
Figure 60. Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Rest of South America, 2017-2027, $ mn 112
Figure 61. Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Middle East and Africa (MEA), 2017-2027, $ mn 114
Figure 62. Breakdown of MEA Amyotrophic Lateral Sclerosis (ALS) Treatment Market by Country, 2020 and 2027, % of Revenue 114
Figure 63. Contribution to MEA 2021-2027 Cumulative Revenue by Country, Value ($ mn) and Share (%) 115
Figure 64. Amyotrophic Lateral Sclerosis (ALS) Treatment Market in UAE, 2017-2027, $ mn 116
Figure 65. Amyotrophic Lateral Sclerosis (ALS) Treatment Market in Saudi Arabia, 2017-2027, $ mn 118
Figure 66. Amyotrophic Lateral Sclerosis (ALS) Treatment Market in South Africa, 2017-2027, $ mn 120
Figure 67. Growth Stage of Global Amyotrophic Lateral Sclerosis (ALS) Treatment Industry over the Forecast Period 123

Related Tags

Related Reports

payment cards

One individual can access, store, display, or archive the report in Excel format but cannot print, copy, or share it. Use is confidential and internal only. License information

One individual can access, store, display, or archive the report in PDF format but cannot print, copy, or share it. Use is confidential and internal only. License information

Up to 10 employees in one region can store, display, duplicate, and archive the report for internal use. Use is confidential and printable. License information

All employees globally can access, print, copy, and cite data externally (with attribution to Bonafide Research). License information

Safe and Secure SSL Encrypted

Quick Contacts

Want to customize this report?

We offer 10% Free Customization at the time of purchase

Get Free Customization

I'm Available

Kavita Mehra

Kavita Mehra

Business Development Manager

Trusted Partners

NONWOVENS_INDUSTRY
FB
issuewire
Financial_Express
logo_yourstory
FB

Budget constraints? Get in touch with us for special pricing

Request Discount

Order Detail

  • Order Placed (08 March, 2026)
  • Notify To Team (08 March, 2026)
  • Report updation (09 March, 2026)
  • Report Quality Check (09 March, 2026)
  • Report Dispatch (10 March, 2026)

  • paypal
  • icici
  • stripe
  • wire-transfer

  • Email
  • Hard Copy

Research Methodology

An Adaptive Approach to Modern-day Research Needs

Get Methodology

Recently Viewed Products

Logo

Global Amyotrophic Lateral Sclerosis (ALS) Treatment Market Outlook, 2030

ChatGPT Summarize Gemini Summarize Perplexity AI Summarize Grok AI Summarize Copilot Summarize

Contact usWe are friendly and approachable, give us a call.

We uses Cookies

We use cookies to ensure you get the best experience on our website.